| Ytd | -79.21% | |
| 1y | -85.70% |
| Open | Prev Close | 1.30 | Low | High | Mkt Cap | 77.50M | |||
| Vol | 0.00 | Avg Vol | 634.44K | EPS | -0.90 | P/E | -1.41 | Forward P/E | -2.71 |
| Beta | 0.60 | Short Ratio | 11.22 | Inst. Own | 63.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.27 | 200-d Avg | 3.58 | 1yr Est | 19.73 |
IGMS News
IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a bio
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Cons
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earni
IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on be
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on be
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on be
Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th f
Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with
BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2,
IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achiev
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Compan
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Cons
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperf
On Wednesday, 311 stocks hit new 52-week lows.
Stocks That Hit 52-Week Highs On Tuesday